Delving into the Latest Updates on Yttrium 90-labelled edotreotide with Synapse

Overview

Basic Info

Drug Type

Peptide Conjugate Radionuclide

Synonyms

90Y-DOTA-D-Phe1-Tyr3-octreotide, OctreoTher, Onalta

+ [7]

Target

SSTR

Mechanism

SSTR agonists(Somatostatin receptor agonists)

Therapeutic Areas

Neoplasms

Active Indication

Neuroendocrine Tumors

Inactive Indication

malignant carcinoid tumor of digestive tract

Originator Organization

Novartis Pharma AG

Active Organization

University of IowaNovartis Pharma AG

Inactive Organization

Molecular Insight Pharmaceuticals, Inc.

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC65H89N14O18S2Y

InChIKeyDUSFGVAHRFYHFD-IEOVAKBOSA-K

CAS Registry189758-25-6

Boost your research with our ADC technology data.

login

or

view full example data

Boost your research with our ADC technology data.

Gene Sequence

Sequence Code 526980110

Source: *****

This is a prospective, pilot, single center, open-label study in patients with metastatic neuroendocrine tumor. Eligible participants will undergo baseline assessments at enrollment. Study participants will receive a one-time administration of 90Y-DOTA-TOC via the hepatic artery.
Participants in the correlative sub-study will receive 68Ga-DOTA-TOC concurrent with the 90Y-DOTA-TOC dose, and undergo additional imaging and assessment.

Start Date01 Jul 2017

Sponsor / Collaborator

The University of California, San Francisco

NCT03044977 / Active, not recruitingEarly Phase 1

Phase 1 Trial Using 131I MIBG and 90Y DOTATOC in a Dosimetrically Determined Optimal Combination for Therapy of Selected Patients With Midgut Neuroendocrine Tumors.

This study is designed to identify the best tolerated doses of [131]Iodine-MIBG and [90]Yttrium-DOTATOC when co-administered to treat midgut neuroendocrine tumors. These drugs (131I-MIBG, 90Y-DOTATOC) are radioactive drugs, known as radionuclide therapy. Currently, the safest and best tolerated doses of these drugs (when combined together) is unknown.

Start Date07 May 2017

Sponsor / Collaborator

University of Iowa

[+3]

100 Clinical Results associated with Yttrium 90-labelled edotreotide

Login to view more data

100 Translational Medicine associated with Yttrium 90-labelled edotreotide

Login to view more data

100 Patents (Medical) associated with Yttrium 90-labelled edotreotide

Login to view more data

136

Literatures (Medical) associated with Yttrium 90-labelled edotreotide

01 Jul 2024·Journal of Vascular and Interventional Radiology

Outcomes in Patients with Macrotrabecular-Massive Subtype Hepatocellular Carcinoma Treated with Yttrium-90 Transarterial Radioembolization

Article

Author: Balli, Huseyin Tugsan ; Erdoğan, Kivilcim Eren ; Piskin, Ferhat Can ; Sozutok, Sinan ; Aikimbaev, Kairgeldy

PURPOSETo compare the outcomes of yttrium-90 transarterial radioembolization (TARE) in patients with hepatocellular carcinoma (HCC) with and without macrotrabecular-massive (MTM) subtypes.MATERIALS AND METHODSForty-one consecutive patients with HCC (male, 90.3%; mean age, 65.3 years [SD ± 10.7]) who underwent yttrium-90 TARE between September 2014 and January 2022 were grouped into the MTM-HCC (n = 17, 41.5%) and non-MTM-HCC (n = 24, 58.5%) groups based on their histopathological subtypes. Demographic, clinical, and radiological characteristics were compared. Survival, univariate, and multivariate analyses were performed, and prognostic factors were evaluated.RESULTSIn MTM-HCC group, the rates of moderately to poorly differentiated tumors were significantly higher (13/17 vs 8/16, P = .007), and new intrahepatic/extrahepatic metastases were detected more frequently (12/17 vs 15/24, P = .038). Median overall survival (OS) in the cohort was 29 months (range, 17.1-40.9 months), whereas patients with MTM-HCC had a significantly shorter median OS (20 vs 44 months, P = .014). In univariate analysis, MTM-HCC subtype (hazard ratio [HR], 2.690; P = .021), the presence of satellite nodules (HR, 3.810; P = .004), and macrovascular invasion (HR, 3.321; P = .012) were identified as significant prognostic factors. In multivariate analysis, MTM-HCC subtype and macrovascular invasion were determined as independent poor prognostic factors (P = .038 and P = .012, respectively).CONCLUSIONSIn patients with HCC treated with yttrium-90 TARE, both the rates of moderately to poorly differentiated histopathological classes and the development of intrahepatic or extrahepatic metastases were significantly higher in the MTM-HCC subtype. OS was worse in patients with MTM-HCC, and macrovascular invasion and MTM-HCC subtype were identified as independent poor prognostic factors.

01 Sep 2023·Journal of neuro-oncology

Somatostatin receptor subtype expression and radiomics from DWI-MRI represent SUV of [68Ga]Ga-DOTATOC PET in patients with meningioma.

Article

Author: Scherfler, Christoph ; Heugenhauser, Johanna ; Iglseder, Sarah ; Uprimny, Christian ; Nevinny-Stickel, Meinhard ; Iglseder, Anna ; Kerschbaumer, Johannes ; Stockhammer, Guenther ; Virgolini, Irene ; Dudas, Jozsef ; Nowosielski, Martha ; Beliveau, Vincent ; Gizewski, Elke R

OBJECTIVEThis retrospective study aimed to analyse the correlation between somatostatin receptor subtypes (SSTR 1-5) and maximum standardized uptake value (SUV_max) in meningioma patients using Gallium-68 DOTA-D-Phe1-Tyr3-octreotide Positron Emission Tomography ([68Ga]Ga-DOTATOC PET). Secondly, we developed a radiomic model based on apparent diffusion coefficient (ADC) maps derived from diffusion weighted magnetic resonance images (DWI MRI) to reproduce SUV_max.METHODThe study included 51 patients who underwent MRI and [68Ga]Ga-DOTATOC PET before meningioma surgery. SUV_max values were quantified from PET images and tumour areas were segmented on post-contrast T1-weighted MRI and mapped to ADC maps. A total of 1940 radiomic features were extracted from the tumour area on each ADC map. A random forest regression model was trained to predict SUV_max and the model's performance was evaluated using repeated nested cross-validation. The expression of SSTR subtypes was quantified in 18 surgical specimens and compared to SUV_max values.RESULTSThe random forest regression model successfully predicted SUV_max values with a significant correlation observed in all 100 repeats (p < 0.05). The mean Pearson's r was 0.42 ± 0.07 SD, and the root mean square error (RMSE) was 28.46 ± 0.16. SSTR subtypes 2A, 2B, and 5 showed significant correlations with SUV_max values (p < 0.001, R2 = 0.669; p = 0.001, R2 = 0.393; and p = 0.012, R2 = 0.235, respectively).CONCLUSIONSSTR subtypes 2A, 2B, and 5 correlated significantly with SUV_max in meningioma patients. The developed radiomic model based on ADC maps effectively reproduces SUV_max using [68Ga]Ga-DOTATOC PET.

01 May 2023·Clinical Nuclear Medicine

Differentiation of a Falcine Meningioma From Cerebral Venous Sinus Thrombosis Using DOTATATE PET

Article

Author: Schlamann, Marc ; Drzezga, Alexander ; Werner, Jan-Michael ; Schroeter, Michael ; Schmidt, Matthias ; Baumann, Claudia ; Fink, Gereon R ; Neuneier, Janina ; Stetter, Isabelle ; Galldiks, Norbert

AbstractDifferentiating brain tumors from nonneoplastic lesions using conventional MRI may be challenging. Clinical symptoms often remain unspecific, and imaging findings from MRI may be inconclusive. We present the case of a 23-year-old woman in whom an MRI suggested a cerebral venous sinus thrombosis. On the other hand, additional atypical MRI findings raised doubts regarding the initial diagnosis. Given the need for a diagnostic procedure with higher sensitivity and specificity for neoplastic tissue, PET with the radiolabeled somatostatin receptor ligand DOTATATE (68Ga-DOTA-d-Phe1-Tyr3-octreotate) was performed. DOTATATE PET facilitated the diagnosis of a falcine meningioma consistent with its value for the differential diagnosis of meningioma.

100 Deals associated with Yttrium 90-labelled edotreotide

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neuroendocrine Tumors	Phase 2	-	Novartis Pharma AG	-
Neuroendocrine Tumors	Phase 2	-	University of Iowa	-
malignant carcinoid tumor of digestive tract	Discovery	-	Molecular Insight Pharmaceuticals, Inc.	01 Jun 2008

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2004	Not Applicable	Neuroendocrine Tumors	60	[Y-90-DOTA,Tyr3]octreotide (4-cycle regimen)	lhcpebvlxe(fxwjyfejml) = muhazaspzq xixtutrzxh (cvyebhidza, 38% less than baseline) View more	-	15 Jul 2004
				[Y-90-DOTA,Tyr3]octreotide (single-cycle regimen)	lhcpebvlxe(fxwjyfejml) = hrwchsqmhx xixtutrzxh (cvyebhidza, 27% less than baseline) View more